<p>阳光生物制药公司（NASDAQ:SBFM）（以下简称 “公司”）是一家提供和开发生命救助药物的制药公司，涵盖肿瘤学、抗病毒药物及其他关键治疗领域。今天，公司宣布以合理的最佳努力方式进行公开发行，预计公司将获得约 600 万美元的总收入，未扣除由公司支付的承销商费用和其他发行费用。</p>
<p>此次发行包括 12,000,000 个普通单位（或预先融资单位），每个单位由（i）一（1）股普通股或一（1）个预先融资认股权证，以及（ii）两个（2）系列 C 认股权证组成，每个认股权证可购买一（1）股普通股，初始行使价格为 0.50 美元。每个普通单位的公开发行价格为 0.50 美元（或每个预先融资单位 0.49999 美元，等于每个普通单位的公开发行价格减去每股 0.00001 美元的行使价格）。预先融资认股权证将立即可行使，并可在完全行使之前的任何时间行使。系列 C 认股权证将立即可行使，并在初始发行日期后五年到期。系列 C 认股权证的行使价格和可发行股份数量将根据最终招股说明书中详细描述的内容进行调整。</p>
<p>预计交易将在 2026 年 5 月 19 日左右完成，前提是满足惯例的交割条件。公司预计将把此次发行的净收益用于一般企业用途和营运资金。</p>
<p><strong>Aegis Capital Corp. 担任此次发行的独家承销商。Sichenzia Ross Ference Carmel LLP 担任公司的法律顾问。Kaufman &amp; Canoles, P.C. 担任 Aegis Capital Corp. 的法律顾问。</strong></p>
<p>一份在 2026 年 5 月 12 日向美国证券交易委员会（“SEC”）提交的 S-1 表格注册声明（编号 333-295800）于 2026 年 5 月 18 日被 SEC 宣布生效。此次发行仅通过招股说明书进行。最终招股说明书将描述发行条款，并将提交给 SEC，届时可在 SEC 网站 www.sec.gov 上获取。最终招股说明书的电子副本可通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas, 27th floor, New York, NY 10105，电子邮件 syndicate@aegiscap.com，或电话 +1 (212) 813-1010 获取，届时可用。在投资此发行之前，感兴趣的各方应完整阅读招股说明书，其中提供了有关公司及该发行的更多信息。</p>
<p>本新闻稿不构成出售要约或购买要约的请求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下进行注册或资格审查之前，此类要约、请求或销售将是非法的。</p>
<p><strong>关于阳光生物制药公司</strong></p>
<p>阳光生物制药目前在加拿大市场销售 60 种仿制处方药，并计划在 2026 年剩余时间内推出 12 种新药。公司还在推进两个专有药物开发项目：</p>
<ul>
<li>K1.1 mRNA，一种针对肝癌的 mRNA-脂质纳米颗粒治疗候选药物。</li>
<li>PLpro 蛋白酶抑制剂，一种针对 SARS 相关冠状病毒感染的小分子抗病毒候选药物。</li>
</ul>
<p>更多信息请访问 www.sunshinebiopharma.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）定义的 “前瞻性声明”。前瞻性声明包括所有不单纯与历史或当前事实相关的声明，包括但不限于关于公司产品开发和商业前景、发行的完成以及发行收益的使用的声明，并可以通过使用 “可能”、“将”、“预计”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明基于公司当前可获得的信息及其当前计划或预期，并受到多种风险和不确定性的影响，这些风险可能会显著影响当前计划，包括在公司向证券交易委员会提交的文件中描述的风险因素。实际结果可能因这些风险而与预期、相信、估计、预期、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的预期是合理的，但公司无法保证未来的结果、表现或成就。除非法律要求，包括美国证券法，公司不打算更新任何前瞻性声明以使这些声明与实际结果相符。</p>
<p>Camille Sebaaly，首席财务官</p>
<p>直线电话：514‑814‑0464</p>
<p>camille.sebaaly@sunshinebiopharma.com</p>
<p><strong>来源：</strong> 阳光生物制药公司</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2Nzc2OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2Nzc2OA"/></p>

SBFM

SBFMW

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Sunshine Biopharma Inc.（纳斯达克代码：SBFM）宣布了一项公开发行的定价，预计将筹集约 600 万美元。此次发行包括 1200 万个普通单位，每个单位定价为 0.50 美元，包含股票和认股权证。该交易预计将在 2026 年 5 月 19 日左右完成，需满足常规条件。筹集的资金将用于一般企业用途。Aegis Capital Corp. 是此次发行的独家配售代理</p>

<p>Sunshine Biopharma Inc. (NASDAQ:SBFM) (the &#34;Company&#34;), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.</p>
<div class="lb-trans"><p>阳光生物制药公司（NASDAQ:SBFM）（以下简称 “公司”）是一家提供和开发生命救助药物的制药公司，涵盖肿瘤学、抗病毒药物及其他关键治疗领域。今天，公司宣布以合理的最佳努力方式进行公开发行，预计公司将获得约 600 万美元的总收入，未扣除由公司支付的承销商费用和其他发行费用。</p>
</div><p>The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchase one (1) share of Common Stock per warrant at an initial exercise price of $0.50. The public offering price per Common Unit is $0.50 (or $0.49999 per Pre-Funded Unit, which is equal to the public offering price per Common Unit minus an exercise price of $0.00001 per share under the Pre-Funded Warrants). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The Series C Warrants will be exercisable immediately and expire five years after the initial issuance date. The exercise price and number of shares issuable under the Series C Warrants are subject to adjustment as described in more detail in the final prospectus to be filed in connection with the offering.</p>
<div class="lb-trans"><p>此次发行包括 12,000,000 个普通单位（或预先融资单位），每个单位由（i）一（1）股普通股或一（1）个预先融资认股权证，以及（ii）两个（2）系列 C 认股权证组成，每个认股权证可购买一（1）股普通股，初始行使价格为 0.50 美元。每个普通单位的公开发行价格为 0.50 美元（或每个预先融资单位 0.49999 美元，等于每个普通单位的公开发行价格减去每股 0.00001 美元的行使价格）。预先融资认股权证将立即可行使，并可在完全行使之前的任何时间行使。系列 C 认股权证将立即可行使，并在初始发行日期后五年到期。系列 C 认股权证的行使价格和可发行股份数量将根据最终招股说明书中详细描述的内容进行调整。</p>
</div><p>The transaction is expected to close on or about May 19, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes and working capital.</p>
<div class="lb-trans"><p>预计交易将在 2026 年 5 月 19 日左右完成，前提是满足惯例的交割条件。公司预计将把此次发行的净收益用于一般企业用途和营运资金。</p>
</div><p><strong>Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman &amp; Canoles, P.C. is acting as counsel to Aegis Capital Corp.</strong></p>
<div class="lb-trans"><p><strong>Aegis Capital Corp. 担任此次发行的独家承销商。Sichenzia Ross Ference Carmel LLP 担任公司的法律顾问。Kaufman &amp; Canoles, P.C. 担任 Aegis Capital Corp. 的法律顾问。</strong></p>
</div><p>A registration statement on Form S-1 (No. 333-295800) previously filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;) on May 12, 2026 was declared effective by the SEC on May 18, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.</p>
<div class="lb-trans"><p>一份在 2026 年 5 月 12 日向美国证券交易委员会（“SEC”）提交的 S-1 表格注册声明（编号 333-295800）于 2026 年 5 月 18 日被 SEC 宣布生效。此次发行仅通过招股说明书进行。最终招股说明书将描述发行条款，并将提交给 SEC，届时可在 SEC 网站 www.sec.gov 上获取。最终招股说明书的电子副本可通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas, 27th floor, New York, NY 10105，电子邮件 syndicate@aegiscap.com，或电话 +1 (212) 813-1010 获取，届时可用。在投资此发行之前，感兴趣的各方应完整阅读招股说明书，其中提供了有关公司及该发行的更多信息。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的请求，也不构成在任何州或司法管辖区内进行这些证券的销售，若在任何此类州或司法管辖区内的证券法下进行注册或资格审查之前，此类要约、请求或销售将是非法的。</p>
</div><p><strong>About Sunshine Biopharma Inc.</strong></p>
<div class="lb-trans"><p><strong>关于阳光生物制药公司</strong></p>
</div><p>Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:</p>
<div class="lb-trans"><p>阳光生物制药目前在加拿大市场销售 60 种仿制处方药，并计划在 2026 年剩余时间内推出 12 种新药。公司还在推进两个专有药物开发项目：</p>
</div><ul>
<li>K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.</li>
<li>PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.</li>
</ul>
<div class="lb-trans"><ul>
<li>K1.1 mRNA，一种针对肝癌的 mRNA-脂质纳米颗粒治疗候选药物。</li>
<li>PLpro 蛋白酶抑制剂，一种针对 SARS 相关冠状病毒感染的小分子抗病毒候选药物。</li>
</ul>
</div><p>Additional information is available at www.sunshinebiopharma.com.</p>
<div class="lb-trans"><p>更多信息请访问 www.sunshinebiopharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, the closing of the offering, and the use of proceeds from the offering, and can be identified by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;project,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;should,&#34; &#34;continue&#34; or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans, including the risk factors described in the Company's documents filed with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned as a result of these risks. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）定义的 “前瞻性声明”。前瞻性声明包括所有不单纯与历史或当前事实相关的声明，包括但不限于关于公司产品开发和商业前景、发行的完成以及发行收益的使用的声明，并可以通过使用 “可能”、“将”、“预计”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明基于公司当前可获得的信息及其当前计划或预期，并受到多种风险和不确定性的影响，这些风险可能会显著影响当前计划，包括在公司向证券交易委员会提交的文件中描述的风险因素。实际结果可能因这些风险而与预期、相信、估计、预期、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的预期是合理的，但公司无法保证未来的结果、表现或成就。除非法律要求，包括美国证券法，公司不打算更新任何前瞻性声明以使这些声明与实际结果相符。</p>
</div><p>Camille Sebaaly, CFO</p>
<div class="lb-trans"><p>Camille Sebaaly，首席财务官</p>
</div><p>Direct Line: 514‑814‑0464</p>
<div class="lb-trans"><p>直线电话：514‑814‑0464</p>
</div><p>camille.sebaaly@sunshinebiopharma.com</p>
<div class="lb-trans"><p>camille.sebaaly@sunshinebiopharma.com</p>
</div><p><strong>SOURCE:</strong> Sunshine Biopharma Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> 阳光生物制药公司</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2Nzc2OA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1167768"/></p>

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering | SBFM Stock News

StockTitan

Sunshine Biopharma

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做空 - Direxion

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

Sunshine Biopharma Inc. 宣布 600 万美元公开发行的定价 | SBFM 股票新闻